

**Shield Therapeutics plc**  
("Shield" or the "Company" or the "Group")

**Shield to Present Abstract at 26th Annual Women's Healthcare Conference 2023 on Accrufer®**

**London, UK - 20 October 2023:**Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency (with or without anemia) reports that an abstract has been accepted for presentation at the National Association of Nurse Practitioners in Women's Health 26th Annual Women's Healthcare Conference taking place October 29 - November 1 in San Diego, California. Dr Michael Cody M.D. will present during Monday, October 30<sup>th</sup> 11:45 am - 1:45 pm and Tuesday, October 31st, 11:30 am - 12:30 pm.

**Poster title:** Iron absorption is maintained over time following repeated twice-daily ferric maltol dosing: Post hoc analysis of a multicenter, open-label, randomized, phase 1 clinical study.

**Poster Presentation Dates and times:** Monday, October 30th; 11:45 am - 1:45 pm; Tuesday, October 31st, 11:30 am - 12:30 pm

NPWH is the leading membership organization for Women's Health Nurse Practitioners and all NPs who perform women's and gender-related healthcare. Through continuing education, advocacy, professional development, and research, we support our members as they strive to continuously improve access to and quality of healthcare for women.

Find out more about the 26th Annual conference here [National Association of Nurse Practitioners in Women's Health \(npwh.org\)](https://npwh.org).

**For further information please contact:**

**Shield Therapeutics plc**  
Greg Madison, CEO

[www.shieldtherapeutics.com](https://www.shieldtherapeutics.com)  
+44 (0) 191 511 8500

**Nominated Adviser and Joint Broker**  
**Peel Hunt LLP**  
James Steel/Patrick Birkholm

+44 (0)20 7418 8900

**Joint Broker**  
**Cavendish Capital Markets Ltd**  
Geoff Nash/ George Dollemore/Nigel Birks

+44 (0)20 7220 0563

**Financial PR & IR Advisor**  
**Walbrook PR**  
Paul McManus/ Alice Woodings

+44 (0)20 7933 8780 or [shield@walbrookpr.com](mailto:shield@walbrookpr.com)

**Investor Contact (US Advisor)**  
**LifeSci Advisors, LLC**  
John Mullaly

+1 617 429 3548 or [jmullaly@lifesciadvisors.com](mailto:jmullaly@lifesciadvisors.com)

**About Iron Deficiency and Accrufer®/Feraccru®**

Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a \$2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, Accrufer® has the potential to meet an important unmet medical need for both physicians and patients.

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. Accrufer®/Feraccru® has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: [www.accrufer.com](https://www.accrufer.com) and [www.feraccru.com](https://www.feraccru.com).

**About Shield Therapeutics plc**

Shield is a commercial stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company launched Accrufer® in the U.S. with an exclusive, multi-year collaboration agreement with Viatri. Outside of the U.S., the Company licensed the rights to four specialty pharmaceutical companies. Feraccru® is commercialized in the UK and European Union by Norgine B.V. (Norgine), which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer®/ Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma), and with KYE Pharmaceuticals Inc. for Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s.  
Accrufer®/Feraccru® are registered trademarks of Shield Therapeutics.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAPPGCWUUPWGUU